SIM
OVID icon

Spark Investment Management’s Ovid Therapeutics OVID Stock Holding History

Spark Investment Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,800
Closed -$78K – 768
2018
Q3 		$78K Buy
+13,800
New +$105K ﹤0.01% 622
2018
Q2 		– Sell
-19,800
Closed -$139K – 709
2018
Q1 		$139K Buy
19,800
+9,000
+83% +$72.8K 0.01% 534
2017
Q4 		$106K Buy
+10,800
New +$99.2K 0.01% 617

Other funds holding OVID

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Spark Investment Management's OVID Position: Q4 2018 in Review

Spark Investment Management sold out of Ovid Therapeutics (OVID) in Q4 2018, closing a stake of 13,800 shares — an estimated $78K sold.

Spark Investment Management first reported a position in OVID in Q4 2017 and held it in 3 quarters. The position peaked at $139K in Q1 2018. 47 funds tracked by Wall St. Rank hold OVID as of Q4 2018.

  • Spark Investment Management reported no remaining Ovid Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Spark Investment Management sold 13,800 Ovid Therapeutics shares in Q4 2018, an estimated $78K.
  • Spark Investment Management first reported a position in Ovid Therapeutics in Q4 2017 and held it in 3 quarters.
  • Spark Investment Management's Ovid Therapeutics position peaked at $139K in Q1 2018.
  • 47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2018.

Based on Spark Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.